Commercial and Partnership Opportunities
VIRTTU is committed to building effective relationships with clinical centres of excellence worldwide and to interacting with committed partners to accelerate this new direction for cancer treatment. By doing so we believe we will be able to maximise future potential and bring the benefits of this ground-breaking therapy to as many people as possible as soon as is safely possible.
We have much to bring to such a relationship including:
- Advanced and protected technology
- Extensive intellectual property portfolio
- A therapeutic platform of significant development potential
- A lead product ready for commercialisation
- Regulatory assets, including IND and Orphan Drug Designation
Our Partners
VIRTTU has enjoyed the support of many prestigious organisations and individuals, some of who we list below and without whom much of our work would not have been possible.We gratefully acknowledge their involvement in this endeavour.
Cincinnati Children's Hospital Medical Center
Solving Kids Cancer
University of Glasgow
Southern General Hospital, Glasgow
We would also particularly like to acknowledge the cancer patients, their families, and the healthcare professionals (including surgeons, oncologists, clinicians, nursing and support staff) that have made the clinical studies possible.
Products
VIRTTU's lead product SEPREHVIR®, a "First in Class" oncolytic virus, shows broad utility against a range of difficult to treat cancers.
Advice and Support for Patients
If you are suffering from any form of cancer or know anyone that is, click here for links to organisations that offer advice and support.